{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-029007","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.940593+00:00","generated_at":"2026-06-18T11:09:17.478993+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cyclacel Q4 net loss $7.4M, cash $18.3M; fadraciclib Phase 2 on track for 1H 2023","bullets":["Net loss Q4 2022 $7.4M, full year $21.2M; cash $18.3M as of Dec 31, 2022.","R&D expenses $6.7M (Q4) and $20.3M (FY) driven by fadraciclib and plogosertib trials.","Cash runway estimated into Q4 2023 including $4.7M UK R&D tax credit receivable.","On track to start oral fadraciclib Phase 2 proof-of-concept in 1H 2023; interim data expected 2H 2023.","Expect final data from fadraciclib dose escalation and initial data from plogosertib dose escalation in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-029007","json":"https://secwatch.observer/filing/0001104659-23-029007.json","markdown":"https://secwatch.observer/filing/0001104659-23-029007.md","text":"https://secwatch.observer/filing/0001104659-23-029007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923029007/0001104659-23-029007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923029007/tm238618d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:09:17.478993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0075d5699cfb3fe5802c23525a7a82a4c72ba7c0","claim":"Bio Green Med Solution, Inc. reported the year ended December 31, 2022 results: net income $21.2 million.","evidence_excerpt":"Net loss for the three months and year ended December 31, 2022, was $7.4 million and $21.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923029007/0001104659-23-029007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$21.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f8096a1f0c714079d556b4d597feb1b9759bc59d","claim":"Bio Green Med Solution, Inc. reported the three months ended December 31, 2022 results: net income $7.4 million.","evidence_excerpt":"Net loss for the three months and year ended December 31, 2022, was $7.4 million and $21.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923029007/0001104659-23-029007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Net income","value":"$7.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}